Active	Status	Sponsor type	Region	Phase	Filter
1 Active 2 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « March » « 2025 » M T W T F S S 24 25 26 27 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6   - « March » « 2025 » M T W T F S S 24 25 26 27 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lirametostat (CPI-1205) / Novartis
ProSTAR, NCT03480646: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer Apr 2020 - Sep 2020 : Updated data from P1/2 ProSTAR trial for mCRPC Data from P1b portion of P1b/2 ProSTAR trial for mCRPC at AACR 2019 [screenshot] Apr 2019 - Apr 2019: Data from P1b portion of P1b/2 ProSTAR trial for mCRPC at AACR 2019 [screenshot] From ProSTAR trial in metastatic prostate cancer [screenshot] May 2018 - May 2018: From ProSTAR trial in metastatic prostate cancer [screenshot]	Active, not recruiting	1b/2	242	US	CPI-1205, Enzalutamide, Abiraterone/Prednisone	Constellation Pharmaceuticals	Metastatic Castration Resistant Prostate Cancer (mCRPC)	12/21	12/21

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lirametostat (CPI-1205) / Novartis
ProSTAR, NCT03480646: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer Apr 2020 - Sep 2020 : Updated data from P1/2 ProSTAR trial for mCRPC Data from P1b portion of P1b/2 ProSTAR trial for mCRPC at AACR 2019 [screenshot] Apr 2019 - Apr 2019: Data from P1b portion of P1b/2 ProSTAR trial for mCRPC at AACR 2019 [screenshot] From ProSTAR trial in metastatic prostate cancer [screenshot] May 2018 - May 2018: From ProSTAR trial in metastatic prostate cancer [screenshot]	Active, not recruiting	1b/2	242	US	CPI-1205, Enzalutamide, Abiraterone/Prednisone	Constellation Pharmaceuticals	Metastatic Castration Resistant Prostate Cancer (mCRPC)	12/21	12/21